People Jolanda de Vries Dendritic cell vaccination

Dendritic Cell therapy

This group focuses on dendritic cell vaccination. Dendritic Cell (DC) therapy represents a promising immunotherapeutic approach for the treatment of cancer. The beauty of DC therapy is that it exploits the body's own immune system to fight cancer.

Research group leader

Jolanda de Vries PhD
full professor

+31 (0)24 365 57 50
contact

Aims

The group's main aim is to keep improving their DC vaccines to reach even better clinical results.

Discoveries

The group is amongst the first (since 1997) investigating the potency of this approach, where DC were isolated or grown from immune cells isolated from the blood of a cancer patient.

read more

Discoveries

The group is amongst the first (since 1997) investigating the potency of this approach, where DC were isolated or grown from immune cells isolated from the blood of a cancer patient. Within specialized cleanrooms, personalized DC vaccines are prepared by activating DC and loading them with tumor antigens. Subsequently, patients are vaccinated.

So far, the group has mainly focused on melanoma, a cancer of the pigmented cells of the skin. The group has treated over 350 patients until now and observed that DC vaccination is well tolerated with minimal side effects. In some patients the group has seen remarkable and long lasting remissions.


Dentritische Celtherapie video in Dutch

Team

Radboud Institute for Molecular Life Sciences

Our main aim is to achieve a greater understanding of the molecular mechanisms of disease. By integrating fundamental and clinical research, we obtain multifaceted knowledge of (patho)physiological processes. read more